Black K L, Mazziotta J C, Becker D P
Division of Neurosurgery, UCLA School of Medicine 90024-1749.
West J Med. 1991 Feb;154(2):186-97.
Recent advances in experimental tumor biology are being applied to critical clinical problems of primary brain tumors. The expression of peripheral benzodiazepine receptors, which are sparse in normal brain, is increased as much as 20-fold in brain tumors. Experimental studies show promise in using labeled ligands to these receptors to identify the outer margins of malignant brain tumors. Whereas positron emission tomography has improved the dynamic understanding of tumors, the labeled selective tumor receptors with positron emitters will enhance the ability to specifically diagnose and greatly aid in the pretreatment planning for tumors. Modulation of these receptors will also affect tumor growth and metabolism. Novel methods to deliver antitumor agents to the brain and new approaches using biologic response modifiers also hold promise to further improve the management of brain tumors.
实验性肿瘤生物学的最新进展正被应用于原发性脑肿瘤的关键临床问题。外周苯二氮䓬受体在正常大脑中分布稀少，而在脑肿瘤中其表达增加了多达20倍。实验研究表明，使用针对这些受体的标记配体来识别恶性脑肿瘤的外缘具有前景。虽然正电子发射断层扫描改善了对肿瘤的动态理解，但带有正电子发射体的标记选择性肿瘤受体将增强特异性诊断的能力，并极大地有助于肿瘤的预处理计划。这些受体的调节也会影响肿瘤的生长和代谢。将抗肿瘤药物输送到大脑的新方法以及使用生物反应调节剂的新途径也有望进一步改善脑肿瘤的治疗。
